Literature DB >> 30267378

Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats.

Camila Hillesheim Horst1, Franciele Schlemmer1, Natália de Aguiar Montenegro1, Ana Carolina Martins Domingues1, Gabriel Ginani Ferreira1, Cínthia Yara da Silva Ribeiro1, Rafael Rocha de Andrade2, Elaine Del Bel Guimarães3, Simoneide Souza Titze-de-Almeida1, Ricardo Titze-de-Almeida4.   

Abstract

Parkinson's disease (PD) is a highly complex brain disorder regarding clinical presentation, pathogenesis, and therapeutics. The cardinal motor signs, i.e., rigidity, bradykinesia, and unilateral tremors, arise in consequence of a progressive neuron death during the prodromal phase. Although multiple transmission systems are involved in disease neurobiology, patients will cross the line between the prodromal and early stage of diagnosed PD when they had lost half of the dopaminergic nigrostriatal cells. As the neurons continue to die ascending the neuroaxis, patients will face a more disabling disease with motor and nonmotor signs. Shedding light on molecular mechanisms of neuron death is an urgent need for understanding PD pathogenesis and projecting therapeutics. This work examined the expression of microRNAs in the striatum of parkinsonian rats chronically exposed to rotenone (2.5 mg/Kg, i.p., daily for 10 days). Rotenone caused motor deficits, the loss of TH(+) cells in the nigrostriatal pathway, and a marked microgliosis. This parkinsonian rat striatum was examined at 26 days after the last rotenone injection, for quantification of microRNAs, miR-7, miR-34a, miR-26a, miR-132, miR-382, and Let7a, by qPCR. Parkinsonian rats presented a significant increase in miR-26a and miR-34a (1.5 and 2.2 fold, respectively, P < 0.05), while miR-7 (0.5 fold, P < 0.05) and Let7a were downregulated. This work reports for first time microRNAs aberrantly expressed in the striatum of rotenone-induced parkinsonian rats, suggesting that this dysregulation may contribute to PD pathogenesis. Beyond revealing new clues of neurodegeneration, our findings might prime further studies targeting miRNAs for neuroprotection or even for diagnosis proposal.

Entities:  

Keywords:  Neurodegeneration; Parkinson’s disease; Rotenone; Striatum; miRNA

Mesh:

Substances:

Year:  2018        PMID: 30267378     DOI: 10.1007/s11064-018-2638-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  62 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration.

Authors:  L C Schmued; K J Hopkins
Journal:  Brain Res       Date:  2000-08-25       Impact factor: 3.252

Review 3.  MicroRNAs in neurodegenerative diseases and their therapeutic potential.

Authors:  Eunsung Junn; M Maral Mouradian
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

Review 4.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

5.  Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration.

Authors:  Lívia H Morais; Marcelo M S Lima; Bruno J Martynhak; Ronise Santiago; Tatiane T Takahashi; Deborah Ariza; Janaína K Barbiero; Roberto Andreatini; Maria A B F Vital
Journal:  Pharmacol Rep       Date:  2012       Impact factor: 3.024

6.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Authors:  R Betarbet; T B Sherer; G MacKenzie; M Garcia-Osuna; A V Panov; J T Greenamyre
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

7.  MicroRNA-7 Regulates the Function of Mitochondrial Permeability Transition Pore by Targeting VDAC1 Expression.

Authors:  Amrita Datta Chaudhuri; Doo Chul Choi; Savan Kabaria; Alan Tran; Eunsung Junn
Journal:  J Biol Chem       Date:  2016-01-22       Impact factor: 5.157

Review 8.  Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease.

Authors:  Ying Wang; Zhaofei Yang; Weidong Le
Journal:  Neurosci Bull       Date:  2017-07-31       Impact factor: 5.203

9.  MicroRNA profiling and the role of microRNA-132 in neurodegeneration using a rat model.

Authors:  Gina Lungu; George Stoica; Andy Ambrus
Journal:  Neurosci Lett       Date:  2013-08-21       Impact factor: 3.046

10.  Brain derived neurotrophic factor (BDNF) expression is regulated by microRNAs miR-26a and miR-26b allele-specific binding.

Authors:  Viviana Caputo; Lorenzo Sinibaldi; Alessia Fiorentino; Chiara Parisi; Caterina Catalanotto; Augusto Pasini; Carlo Cogoni; Antonio Pizzuti
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more
  9 in total

Review 1.  Parkinson's disease and microRNAs - Lessons from model organisms and human studies.

Authors:  Brian Evans; Howard A Furlong; Alexandre de Lencastre
Journal:  Exp Gerontol       Date:  2021-10-08       Impact factor: 4.032

Review 2.  "Metal elements and pesticides as risk factors for Parkinson's disease - A review".

Authors:  Inam Ullah; Longhe Zhao; Yang Hai; Muhammad Fahim; Dhafer Alwayli; Xin Wang; Hongyu Li
Journal:  Toxicol Rep       Date:  2021-03-10

3.  MicroRNA‑34a‑5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study.

Authors:  Ilaria Grossi; Annalisa Radeghieri; Lucia Paolini; Vanessa Porrini; Andrea Pilotto; Alessandro Padovani; Alessandra Marengoni; Alessandro Barbon; Arianna Bellucci; Marina Pizzi; Alessandro Salvi; Giuseppina De Petro
Journal:  Int J Mol Med       Date:  2020-12-02       Impact factor: 4.101

Review 4.  Non-coding RNAs and their bioengineering applications for neurological diseases.

Authors:  Tuhin Das; Tushar Kanti Das; Anne Khodarkovskaya; Sabyasachi Dash
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 5.  Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson's Disease Pathogenesis: A Narrative Review.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Sokratis G Papageorgiou; Christina Piperi
Journal:  Brain Sci       Date:  2022-01-28

Review 6.  A genome on shaky ground: exploring the impact of mitochondrial DNA integrity on Parkinson's disease by highlighting the use of cybrid models.

Authors:  Martin Lang; Anne Grünewald; Peter P Pramstaller; Andrew A Hicks; Irene Pichler
Journal:  Cell Mol Life Sci       Date:  2022-05-05       Impact factor: 9.207

Review 7.  Role of MicroRNAs in Parkinson's Disease.

Authors:  Suh Yee Goh; Yin Xia Chao; Shaikali Thameem Dheen; Eng-King Tan; Samuel Sam-Wah Tay
Journal:  Int J Mol Sci       Date:  2019-11-12       Impact factor: 5.923

Review 8.  MicroRNA-7: expression and function in brain physiological and pathological processes.

Authors:  Juanjuan Zhao; Ya Zhou; Mengmeng Guo; Dongxu Yue; Chao Chen; Guiyou Liang; Lin Xu
Journal:  Cell Biosci       Date:  2020-06-10       Impact factor: 7.133

9.  Parkinson mice show functional and molecular changes in the gut long before motoric disease onset.

Authors:  Manuela Gries; Anne Christmann; Steven Schulte; Maximilian Weyland; Stephanie Rommel; Monika Martin; Marko Baller; Ralph Röth; Stefanie Schmitteckert; Marcus Unger; Yang Liu; Frederik Sommer; Timo Mühlhaus; Michael Schroda; Jean-Pierre Timmermans; Isabel Pintelon; Gudrun A Rappold; Markus Britschgi; Hilal Lashuel; Michael D Menger; Matthias W Laschke; Beate Niesler; Karl-Herbert Schäfer
Journal:  Mol Neurodegener       Date:  2021-06-02       Impact factor: 14.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.